Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.81 |
| ▸ | NT5E | P21589 | 1/20 | 0.76 |
| ▸ | KRAS | P01116 | 2/20 | 0.76 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.75 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.71 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.65 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gtp SCHEMBL3333959 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376140 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL18784960 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376139 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL19691775 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL2593095 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL17367368 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL96708 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634185-A1 | A NOVEL SMALL MOLECULE KRAS INHIBITOR: DRUGGING UNDRUGGABLE TARGETS FOR CANCER THERAPEUTICS | Pillai Universal LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024127214-A1 | A NOVEL SMALL MOLECULE KRAS INHIBITOR: DRUGGING UNDRUGGABLE TARGETS FOR CANCER THERAPEUTICS | PILLAI UNIVERSAL LLC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220144860-A1 | FLUORESCENT GTP ANALOGUES AND USE | CISBIO BIOASSAYS (FR) | 2022-05-12 | — | — | US | disclosed |
| US-11185100-B2 | Methods for modulating taste receptors | MARS, INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190021380-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | TGM2 1916/4885NT5E 32/4885KRAS 1439/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | TGM2 1916/4885NT5E 32/4885KRAS 1439/4885 |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | RELA, NFKBIA, NFKB1 | TGM2 1947/4885NT5E 2992/4885KRAS 145/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | TGM2 3027/4885NT5E 2746/4885KRAS 3753/4885 |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | TGM2 1947/4885NT5E 2992/4885KRAS 145/4885 |
| US-20220144860-A1 | FLUORESCENT GTP ANALOGUES AND USE | GNAI3, GNAQ, GNB1 | TGM2 140/4885NT5E 344/4885KRAS 9/4885 |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | TGM2 1947/4885NT5E 2992/4885KRAS 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.